|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||77.65 - 78.93|
|52-week range||57.17 - 89.74|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||21.82|
|Earnings date||26 Apr 2023 - 01 May 2023|
|Forward dividend & yield||3.00 (3.78%)|
|Ex-dividend date||14 Mar 2023|
|1y target est||88.96|
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.